Shoreline Biosciences Announces $43m Financing
Co-founded by Stork Capital and led by Stork Capital’s Life Sciences Chairman Kleanthis G. Xanthopoulos, Ph.D.
San Diego, Calif., January 2021– Shoreline Biosciences, Inc., (Shoreline), an emerging biotechnology company developing intelligently designed allogeneic off-the-shelf cellular immunotherapies derived from induced Pluripotent Stem Cells (iPSC) for cancer and other serious diseases, announced the completion of a $43M financing, led by Boxer Capital, with participation from BVF, Commodore, Cormorant, Janus, Logos, Gilead, Wedbush in addition to Stork Capital, and other investors.
The proceeds from the financing will allow Shoreline to accelerate the advancement of its proprietary induced pluripotent stem cell platform focused on developing next generation NK-cell and macrophage-cell therapies, while also supporting research efforts to create potent and persistent NK-specific CARs and macrophage-specific CARs and NK engagers.
“We are thrilled to have the support of such outstanding investors who share our vision and commitment to build a differentiated and exciting cell therapy company with the ambition to lead the next wave of transformative cell therapies,” said Kleanthis G. Xanthopoulos, Ph.D., Shoreline Co-Founder and Executive Chairman. “With this financing, we are well positioned to drive our program to the clinic in at least two indications.
Stork Capital aims to invest in companies that are pushing the boundaries of scientific innovation and Shoreline is doing exactly that. Shoreline Biosciences’ approach to intelligently designing iPSC-derived cell therapies will take immunotherapy and personalized medicine to new heights.
Shoreline stood out from other companies in the cell therapy space with their unique focus on genetic reprogramming of the IL-15/CISH and ADAM17 pathways, which have been shown to lead to enhanced metabolic fitness, persistence of the engineered NK cells and enhanced ADCC to improve anti-cancer activity.”
About Shoreline Biosciences
Shoreline is an emerging biotechnology company dedicated to advancing the development of intelligently designed allogeneic off-the-shelf cellular immunotherapies for cancer and other serious diseases. Shoreline is building a pipeline of natural killer (NK)-cell and macrophage-cell therapy candidates derived from its deep expertise in iPSC differentiation methods and genetic reprogramming of known cancer pathways. Shoreline Biosciences is headquartered in San Diego Jolla, CA. For more information, please visit https://shorelinebio.com/ and engage with us on LinkedIn.